Search results for "Hydropic degeneration"

showing 2 items of 2 documents

Histopathological findings in oral lichen planus and their correlation with the clinical manifestations

2010

Objectives: To highlight the most characteristic histopathological findings of oral lichen planus and their correlation with the clinical manifestations and forms. Study design: We performed a retrospective study of 50 biopsied and diagnosed cases of oral lichen planus obtained over a period of 11 years, spanning from May 1998 to April 2009. We analyzed the age and sex of the patient, type of lichen planus, location and different histopathological findings, comparing them with the clinical lesions. Results: Seventy eight percent of the patients are female and 22% are male, with an average age of 56.06 years for both sexes. The most frequent clinical form is reticular, present in 78% of the …

AdultMalePathologymedicine.medical_specialtyEpithelial dysplasiaHyperkeratosisAcanthosisHydropic degenerationstomatognathic systemOral and maxillofacial pathologymedicineAtypiaHumansskin and connective tissue diseasesGeneral DentistryAgedRetrospective StudiesAged 80 and overintegumentary systembusiness.industryMiddle AgedHyperplasia:CIENCIAS MÉDICAS [UNESCO]medicine.diseasestomatognathic diseasesOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASFemaleSurgeryOral lichen planusbusinessLichen Planus Oral
researchProduct

Cyclosporine A + Glybenclamide. Effect on Glucose Metabolism: Preliminary Results

1989

Cyclosporine A (CsA) is an immunosuppressive drug which determines, at high dosage, glucose intolerance (1). Different drugs present a pharmacological interaction with CsA increasing or reducing its blood level (2). To investigate the role of Glybenclamide (HB419), a sulphonilureic oral antidiabetic drug of large use, on CsA glucose metabolic effect, we have administered CsA + HB419 in rats. The aim of our work is to evaluate if HB419 influences CsA blood levels and if it improves glucose tolerance.

Blood levelDrugbusiness.industrymedicine.medical_treatmentmedia_common.quotation_subjectCarbohydrate metabolismPharmacologymedicine.diseaseHydropic degenerationImmunosuppressive drugHigh dosageMetabolic effectsmedicinebusinessmedia_common
researchProduct